Hepatology research : the official journal of the Japan Society of Hepatology · 2025
Efficacy and Safety of Direct Oral Anticoagulants in Budd-Chiari Syndrome After Percutaneous Recanalization.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Chengjian, Shen Yi, Gao Zhaoyan, Wang Xiaoze, Liu Guofeng, Luo Xuefeng
Аннотация
BACKGROUND AND AIMS: Direct oral anticoagulants (DOACs) are increasingly used in various thrombotic disorders. However, data on the use of DOACs in patients with Budd-Chiari syndrome (BCS) remain limited. We aimed to assess the efficacy and safety of DOACs in patients with BCS after percutaneous recanalization.
METHODS: We carried out a single-center retrospective analysis of patients with primary BCS who received DOACs or vitamin K antagonists (VKAs) after percutaneous recanalization. The primary endpoints were the cumulative primary and secondary patency rates. Secondary endpoints included bleeding events and death.
RESULTS: A total of 236 patients were included, with 133 receiving DOACs (rivaroxaban, n = 59; dabigatran, n = 74) and 103 receiving VKAs. The median duration of anticoagulation was 18.8 months (IQR: 6.3-28.6) in the DOAC group (median follow-up: 22.8 months, IQR: 12.6-31.8) and 32.2 months (IQR: 6.0-73.5) in the VKA group (median follow-up: 70.6 months, IQR: 39.0-85.6). The 1-, 2-, and 3-year cumulative primary patency rates were 79.3%, 70.0%, and 62.9% in the DOAC group, compared to 83.5%, 78.2%, and 73.8% in the VKA group (p = 0.269). Furthermore, no significant differences were observed between the DOAC and VKA groups in major bleeding rates (DOAC: 1.8 per 100 person-years; VKA: 2.8 per 100 person-years; incidence rate ratio [IRR]: 1.6, 95% CI: 0.4-5.9; p = 0.436).
CONCLUSION: DOACs may be an effective and safe alternative to VKAs for patients with BCS after percutaneous recanalization. Further prospective studies are needed to confirm these findings.
METHODS: We carried out a single-center retrospective analysis of patients with primary BCS who received DOACs or vitamin K antagonists (VKAs) after percutaneous recanalization. The primary endpoints were the cumulative primary and secondary patency rates. Secondary endpoints included bleeding events and death.
RESULTS: A total of 236 patients were included, with 133 receiving DOACs (rivaroxaban, n = 59; dabigatran, n = 74) and 103 receiving VKAs. The median duration of anticoagulation was 18.8 months (IQR: 6.3-28.6) in the DOAC group (median follow-up: 22.8 months, IQR: 12.6-31.8) and 32.2 months (IQR: 6.0-73.5) in the VKA group (median follow-up: 70.6 months, IQR: 39.0-85.6). The 1-, 2-, and 3-year cumulative primary patency rates were 79.3%, 70.0%, and 62.9% in the DOAC group, compared to 83.5%, 78.2%, and 73.8% in the VKA group (p = 0.269). Furthermore, no significant differences were observed between the DOAC and VKA groups in major bleeding rates (DOAC: 1.8 per 100 person-years; VKA: 2.8 per 100 person-years; incidence rate ratio [IRR]: 1.6, 95% CI: 0.4-5.9; p = 0.436).
CONCLUSION: DOACs may be an effective and safe alternative to VKAs for patients with BCS after percutaneous recanalization. Further prospective studies are needed to confirm these findings.